Literature DB >> 30255976

Infliximab for the treatment of Kawasaki disease.

Tomoyo Matsubara1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30255976     DOI： 10.1111/ped.13663

Source DB:  PubMed          Journal:  Pediatr Int        ISSN： 1328-8067            Impact factor:   1.524


× No keyword cloud information.
  3 in total

1.  Interleukin-33/ST2 Axis as Potential Biomarker and Therapeutic Target in Kawasaki Disease.

Authors:  Seigo Okada; Hiroki Yasudo; Yuji Ohnishi; Chie Matsuguma; Reiji Fukano; Takahiro Motonaga; Takako Waniishi; Shunji Hasegawa
Journal:  Inflammation       Date:  2022-10-08       Impact factor: 4.657

2.  Resolution of Giant Coronary Aneurisms in a Child With Refractory Kawasaki Disease Treated With Anakinra.

Authors:  Alessandro Gambacorta; Danilo Buonsenso; Gabriella De Rosa; Ilaria Lazzareschi; Antonio Gatto; Federica Brancato; Davide Pata; Piero Valentini
Journal:  Front Pediatr       Date:  2020-05-07       Impact factor: 3.418

Review 3.  Coronary Vasculitis.

Authors:  Tommaso Gori
Journal:  Biomedicines       Date:  2021-05-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.